Vaccines strengthen our immune systems by exposing white blood cells to disease-specific antigens. This builds a depot of memory T cells, so in the case of a full-on infection, our bodies can fight off malicious organisms with greater ease. Dr. Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases, has been working to develop an HIV vaccine for the past 30 years. This revolutionary medical tool would help reduce the dreadful effects of AIDS on the world population, for many years to come. Researchers can test a vaccine’s efficacy, post-injection, by measuring the production of antibodies. Antibodies are highly specific proteins produced by B cells and are generally found circulating within our blood. In order to quantify these microscopic proteins, researchers must use precise sample preparation techniques that separate antibodies from the other blood components. Most commonly, high performance liquid chromatography (HPLC) is used to filter blood serum, and to detect the presence of antibodies. During this procedure, a liquid is transferred into a glass tube containing a polar column, often made of silicon. A non-polar solvent is then applied to filter out particular substances for ensuing analyses. For scientists such as Dr. Fauci, this technique helps measure the quantitative effect of a vaccine and represents an important step in the journey to developing a successful treatment for AIDS.

Here at BioInformatics, we want to help you understand the current market for HPLC and where it’s headed, so that you can make the most informed business decision as possible. Although this technique has many applications in the fields of analytical chemistry and biochemistry, it plays an especially critical role in the pharmaceutical industry. Most of these companies are highly dependent on research and development, and patent expiry consistently drives the need for novel drug treatments. Typically, companies utilize HPLC to test products and detect the molecular ingredients used during the manufacturing process. Due to persistent growth in the pharmaceuticals industry, the chromatography market reached $8.8 billion in sales in 2017.

The market for HPLC is fairly mature in terms of technological advancement, as many different suppliers are currently promoting their new, highly sophisticated products. For example, Phenomenex recently debuted their bioZen series of liquid chromatography, which features new biocompatible titanium hardware and much analytical flexibility. Efforts to manufacture drugs with high purity yields, at tremendously high production volumes, will promote future technological improvements and competition among HPLC suppliers. Companies can successfully differentiate their initial systems, win new customers, and firmly establish their share of the market, by developing innovative and cutting-edge products. On April 9th, Analytik announced the release of new instrumentation that combines their PlasmaQuant mass spectrometer with HPLC. Their CEO, Ulrich Krauss, succinctly described the functionality of this new instrument, “…Not only is this interesting for special analyses, but it makes an entire series of routine analyses more efficient, quicker, and more accurate.”

Stay tuned for our next article in this series that will provide further evaluations and sample data from our newest release: HPLC 2018 Market Analysis and Perspectives report. This report is an extension of the HPLC section within our 2018 Global Assessment Report. It further details sub technologies as well as end-user perspectives not included in the Global Assessment report. Feel free to refer to our HPLC 2018 Market Analytics and Perspectives report brochure for more information.

.

Some of this content originally appeared in Instrument Business Outlook – the leading publication covering the analytical instrument and life science industries.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *